Extraordinary use

Health Canada recognizes that there are circumstances in which manufacturers cannot reasonably provide substantial evidence demonstrating the safety and efficacy of a therapeutic product as there are logistical or ethical challenges in conducting the appropriate human clinical trials. For these types of products, which may be needed as part of emergency preparedness in Canada, the regulations for Extraordinary Use New Drugs (EUND) allow for the possibility of a market authorization based primarily on animal data.

Once a product has received market authorization as an EUND, the sale of the product for that indication is restricted to federal, provincial and territorial, and municipal government(s).

New drugs


(new active substance)

Medical ingredient:

Anthrax Immune Globulin (Human)


Anthrasil is used to treat inhalational anthrax, a bacterial infection.

For more information, see the Regulatory Decision Summary.

Page details

Date modified: